Live Update from ESMO: Medivir

Live Update from ESMO: Medivir

2024-09-16

11:45-12:45

Live broadcast at redeye.se/events

English language

2024-09-16

11:45-12:45

Live broadcast at redeye.se/events

English language

Live broadcast at redeye.se/events

English language

Live broadcast at redeye.se/events

English language

Medivir presents mature clinical data for fostrox + Lenvima in liver cancer (HCC) at the European Society for Medical Oncology (ESMO) Congress, Barcelona on Sep 16th 2024.

Follow a live broadcast presentation and interview afterward from Barcelona, allowing participants to send in questions beforehand.

Introduction – Fostrox, designed to target liver cancer
Dr Pia Baumann, Chief Medical Officer, Medivir AB

Fostrox + Lenvatinib in second-line HCC

Results & clinical experience from Phase 1b/2a study
Data in the context of current clinical practice in second-line HCC

Dr. Hong Jae Chon, CHA Bundang Hospital, Seoul, Korea

Fostrox + Lenvatinib moving forward.

Dr Pia Baumann, Chief Medical Officer, Medivir AB

NOTE

Companies and schedules may change before the event starts. Save the date to your calendar by using Add to calendar.